LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
NCT02450903
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG:
LDK378
Sponsor
Novartis Pharmaceuticals